Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings

Conclusion:Barostim may be a cost-effective treatment when compared with optimal medical management in patients with resistant hypertension.
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Hypertension management Source Type: research